In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 813-821

  Kobayashi, Masanori ^a   Yoshinaga, Tomokazu ^a   Seki, Takahiro ^a   Wakasa Morimoto, Chiaki ^a   Brown, Kevin W ^b   Ferris, Robert ^b   Foster, Scott A ^b,c   Hazen, Richard J ^b   Miki, Shigeru ^a   Suyama Kagitani, Akemi ^a   Kawauchi Miki, Shinobu ^a   Taishi, Teruhiko ^a   Kawasuji, Takashi ^a   Johns, Brian A ^b   Underwood, Mark R ^b   Garvey, Edward P ^b,d   Sato, Akihiko ^a   Fujiwara, Tamio ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b GLAXOSMITHKLINE   (United States)

^c Chimerix Inc   (United States)

^d Viamet Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; S GSK 1349572; STAVUDINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-HIV AGENTS; CELL LINE; CELL LINE, TRANSFORMED; DRUG RESISTANCE, VIRAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NAPHTHYRIDINES; T-LYMPHOCYTES; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 78751697293     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01209-10     Document Type: Article

References (43)

1. Adachi, A., et al. 1986. Production of acquired immunodeficiency syndrome-ssociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291. (Pubitemid 16013975)
2. Bacheler, L., et al. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999-5008.
3. Bacheler, L. T., et al. 2000. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44:2475-2484.
4. Billich, A. 2003. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Investig. Drugs 4:206-209.
5. Boros, E. E., B. A. Johns, E. P. Garvey, C. S. Koble, and W. H. Miller. 2006. Synthesis and HIV-integrase strand transfer inhibition activity of 7-hydroxy[1,3]thiazolo[5,4-b]pyridin-5(4H)-ones. Bioorg. Med. Chem. Lett. 16:5668-5672.
6. Boucher, C. A., et al. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
7. Caliendo, A. M., et al. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
8. Ceccherini-Silberstein, F., et al. 2009. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 11:17-29.
9. Chackerian, B., E. M. Long, P. A. Luciw, and J. Overbaugh. 1997. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J. Virol. 71:3932-3939.
10. Charpentier, C., et al. 2010. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS 24:2753-2755.
11. Cooper, D. A., et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
12. Daluge, S. M., et al. 1994. 5-Chloro-2′,3′-dideoxy-3′- fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 38:1590-1603.
13. DeJesus, E., et al. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatmentnaive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5.
14. Egbertson, M. S., et al. 2007. A potent and orally active HIV-1 integrase inhibitor. Bioorg. Med. Chem. Lett. 17:1392-1398.
15. Garvey, E. P., et al. 2008. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob. Agents Chemother. 52:901-908.
16. Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566. (Pubitemid 16239336)
17. Hazuda, D. J., et al. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
18. Hazuda, D. J., M. D. Miller, B. Y. Nguyen, and J. Zhao. 2007. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase 2 study in patients with triple-class resistant HIV-1 infection. XVI Int. HIV Drug Resist. Workshop, Barbados, West Indies. http://www.natap.org/2007/ResisWksp/ ResisWksp-37.htm.
19. Hoggard, P. G., S. Kewn, M. G. Barry, S. H. Khoo, and D. J. Back. 1997. Effects of drugs on 2′,3′-dideoxy-2′,3′- didehydrothymidine phosphorylation in vitro. Antimicrob. Agents Chemother. 41:1231-1236.
20. Isaka, Y., et al. 1999. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology 264:237-243.
21. Jármy, G., M. Heinkelein, B. Weissbrich, C. Jassoy, and A. Rethwilm. 2001. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. J. Med. Virol. 64:223-231.
22. Jones, G. S., et al. 2009. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob. Agents Chemother. 53:1194-1203.
23. Kempf, D. J., et al. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
24. Kobayashi, M., et al. 2008. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 80:213-222.
25. Lalezari, J., et al. 2009. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-naïve HIV-1-infected patients, abstr. TUAB105. Fifth Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa.
26. Lataillade, M., J. Chiarella, and M. J. Kozal. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 12:563-570.
27. Ledford, R., N. Margot, M. Miller, and D. McColl. 2007. Elvitegravir (GS-9137/JTK-303), an HIV-1 integrase inhibitor, has additive to synergistic interactions with other antiretroviral drugs in vitro, abstr. MOPEA052. Fourth Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment and Prevention, Sydney, Australia. http://www.ias2007.org/pag/Abstracts.aspx?SID=153&AID=4041.
28. Malet, I., et al. 2009. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J. Antimicrob. Chemother. 63:795-804.
29. Marinello, J., et al. 2008. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47:9345-9354.
30. Markowitz, M., et al. 2007. Rapid onset and durable antiretroviral effect of raltegravir (MK-0518), a novel HIV-1 integrase inhibitor, as part of combination ART in treatment of HIV-1 infected patients: 48-week data, abstr. TUPAB104. Fourth Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment and Prevention, Sydney, Australia. http://www.ias2007.org/pag/Abstracts.aspx?SID= 48&AID=3027.
31. Markowitz, M., et al. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
32. McColl, D. J., et al. 2007. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase 2 study of elvitegravir (GS-9137), abstr. 9. XVI Int. HIV Drug Resist. Workshop, Bridgetown, Barbados. http://www.natap.org/2007/ResisWksp/ResisWksp-43.htm.
33. Min, S., et al. 2010. Pharmacokinetics and safety of S/GSK1349572, a nextgeneration HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54:254-258.
34. Nakahara, K., et al. 2009. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res. 81:141-146.
35. Palmer, S., R. W. Shafer, and T. C. Merigan. 1999. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 13:661-667.
36. Partaledis, J. A., et al. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
37. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205.
38. Rockstroh, J. K. 2009. Integrase inhibitors: why do we need a new drug class for HIV therapy? Eur. J. Med. Res. 14(Suppl. 3):1-3.
39. Selleseth, D. W., et al. 2003. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother. 47:1468-1471.
40. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 90:5653-5656.
41. Tukey, J. W., J. L. Ciminera, and J. F. Heyse. 1985. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41:295-301.
42. Underwood, M., B. Johns, A. Sato, T. Fujiwara, and W. Spreen. 2009. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy, abstr. WEPEA098. Fifth Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa. http://www.ias2009.org/pag/PDF/2051.pdf.
43. Zolopa, A. R., et al. 2007. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients, abstr. 143LB. Fourteenth Conf. Retrovir. Opportunistic Infect., Los Angeles, CA. http://www.retroconference.org/2007/Abstracts/30571.htm.